Achillion Reports 100% Sustained Virologic Response Rate From Phase 2 Trial

(RTTNews) - Achillion Pharmaceuticals, Inc. (ACHN) Friday announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, the company's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus infection. The company's stock is gaining 12 percent in pre-market activity.

The study is open-label, randomized, partial-crossover to evaluate the efficacy, safety, and tolerability of eight weeks or six weeks of ACH-3102 and sofosbuvir, a marketed nucleotide polymerase inhibitor, without ribavirin, in treatment-naïve genotype 1 HCV-infected patients.

The primary objective of the study is determination of sustained viral response 12 weeks after the completion of therapy. Eighteen patients were enrolled, including six observational patients.

Of the 12 patients treated, 100 percent remained HCV RNA undetectable four weeks after completing therapy.

Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.

ACHN, which closed up 6.7 percent on Thursday at $8.44, is gaining 12 percent in pre-market activity.